pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,329 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT860Endpoints665BioPharma Dive251onclive165BioSpace115Fierce Biotech112raps43globenewswire health
therapy area
allOncology5158Rare Disease933Cardiology889Hematology799Immunology772Pulmonology619Psychiatry & CNS
  • Latigo and BlossomHill file Nasdaq IPO plans to fund pain and cancer pipelines
    Latigo Biotherapeutics and BlossomHill Therapeutics, both based in California, have filed applications to list on the Nasdaq Global Select Market. Latigo aims to raise up to $285.2 million to advan…
    BioSpace · 13h agoDealNeutral↗ source
  • Pfizer adds $2.5 billion to cost-cutting plan, pushing total savings past $10 billion
    Pfizer announced on Tuesday an additional $2.5 billion of cost reductions across the company, extending its multi-year austerity program. The new cuts bring the cumulative savings effort to more t…
    Endpoints · 14h agoNegative↗ source
← prev
page 2 of 54
next →
36
fda recalls29
fda press21
fda medwatch21
611
Vaccines535
Endocrinology & Metabolism305
Ophthalmology280
Infectious Disease266
Pain264
  • US-China biotech rivalry sparks calls for deeper discussion, says editor
    The editor notes that the ongoing debate over the competitive relationship between U.S. and Chinese biotechnology sectors has been unfolding over recent months. While many knowledgeable voices are…
    Endpoints · 7h agoNegative↗ source
  • Amgen drops early-stage obesity drug candidate AMG-513
    Amgen announced it is discontinuing its early-stage obesity candidate AMG-513. The program was in Phase 1, but the company provided no details about the study or the reasons for the halt. A spokes…
    Endpoints · 6h agoNegative↗ source
  • Lisata Therapeutics cuts 72% of staff after merger with Kuva falls through and files lawsuit
    Lisata Therapeutics announced it is cutting about 72% of its full‑time workforce after a planned merger with Kuva Labs collapsed. The company had 21 full‑time employees at the end of 2025, so roug…
    BioSpace · 7h agoLayoffsNegative↗ source
  • Vertex unfazed by competitive IgAN space as FDA verdict looms
    Positive two-year follow-up data for Otsuka Pharmaceuticals’ IgA nephropathy drug Voyxact could support the FDA’s ongoing review of Vertex Pharmaceuticals’ povetacicept, CEO Reshma Kewalramani said…
    BioSpace · 15h agoEarningsNeutral↗ source
  • Novo vs. Lilly: Q2's cardiometabolic grudge match
    For years, Novo Nordisk and Eli Lilly have dominated the conversation surrounding obesity medicines as the duopoly competes to lead the largest pharmaceutical category in history. While dozens of c…
    Endpoints · 11h agoNeutral↗ source
  • CLINUVEL to cut up to 20% of staff and move headquarters to New York
    CLINUVEL announced a strategic reorganization aimed at focusing resources on the U.S. market. The company will reduce its global workforce by 10% to 20%, affecting up to 21 of its 104 employees.…
    BioSpace · 11h agoLayoffsNegative↗ source
  • Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout
    Pfizer has axed two clinical-stage obesity programs, dropping a GLP-1 receptor agonist from the Metsera buyout and a GIPR antagonist as part of its quarterly pipeline cleanout.
    Fierce Biotech · 17h ago↗ source
  • KKR inks $5.7B deal to take medtech manufacturing giant Integer private
    Private equity giant KKR is expanding its healthcare portfolio with a deal to take medtech manufacturing giant Integer private for approximately $5.7 billion.
    Fierce Biotech · 17h ago↗ source
  • Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavx
    Latigo Biotherapeutics has fleshed out its plans for an IPO to finance the development of its clinical-stage pipeline of non-opioid pain management drugs.
    Fierce Biotech · 18h ago↗ source
  • Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials
    A phase 2 trial of Merck & Co.’s anti-TL1A monoclonal antibody has missed its primary endpoint, closing off one avenue for expansion of an asset acquired in a $10.8 billion takeover. The setback wa…
    Fierce Biotech · 21h ago↗ source
  • Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pact
    Pathos AI has agreed to pay $125 million for a bispecific antibody-drug conjugate from China’s Alphamab Oncology, while adding a Big Pharma partner in the form of AstraZeneca.
    Fierce Biotech · 21h ago↗ source
  • FDA expands Pluvicto label, allowing most metastatic prostate cancer patients to receive the therapy
    The U.S. Food and Drug Administration has approved an expanded label for Novartis’ radiopharmaceutical Pluvicto, permitting its use together with hormone therapy in metastatic prostate cancer. The…
    Endpoints · 1d agoApprovalPositive↗ source
  • Supernus and Indivior merge to form CNS-focused company with 11 marketed drugs and $2.2B revenue target
    Supernus Pharmaceuticals and Indivior Pharmaceuticals announced an all‑stock merger of equals, creating a central nervous system‑focused company that will combine their product lines and operations…
    BioSpace · 1d agoDealPositive↗ source
  • Curium to acquire Lantheus in deal valued up to $8 billion
    Curium announced it will purchase all outstanding shares of Lantheus for $102.50 cash per share, with potential additional $12 per share via contingent value rights linked to sales milestones in pr…
    Fierce Biotech · 1d agoDealNeutral↗ source
  • Wall Street reacts negatively to AstraZeneca-Bristol Myers merger talks, shares tumble
    A report in the Financial Times, followed by Reuters, said AstraZeneca and Bristol Myers Squibb have been discussing a possible combination in recent months. The news triggered a sharp sell-off. A…
    BioPharma Dive · 1d agoDealNegative↗ source
  • Novo Nordisk’s Phase 3 failure of IL-6 drug ziltivekimab rattles inflammation-focused pipeline
    Novo Nordisk reported that its late-stage IL-6 inhibitor ziltivekimab did not achieve its primary goal in the Phase 3 ZEUS trial, which was designed to lower cardiovascular complications. The disa…
    BioSpace · 1d agoNegative readoutNegative↗ source
  • Analysts deem AstraZeneca-BMS merger unlikely despite market buzz
    Analysts say that talks between AstraZeneca and Bristol Myers Squibb are unlikely to result in a merger because the two companies have overlapping product lines that would attract heavy antitrust s…
    BioSpace · 1d agoDealNeutral↗ source
  • Curium to acquire Lantheus in $8 billion deal, offering $102.5 per share with upside potential
    Curium announced it will purchase radiopharmaceutical company Lantheus in a transaction valued at about $8 billion. The agreement sets the purchase price at $102.5 for each Lantheus share, and inc…
    Endpoints · 1d agoDealNeutral↗ source
  • Phase 3 failure of AstraZeneca/Ionis antisense drug Wainua shakes ATTR-CM market, opens space for other developers
    AstraZeneca and Ionis Pharmaceuticals reported that their antisense therapy Wainua did not achieve a significant cardiovascular benefit in a Phase 3 trial for transthyretin amyloid cardiomyopathy (…
    BioSpace · 1d agoNegative readoutNeutral↗ source
  • Analyst warns AstraZeneca-BMS merger could spark regulatory hurdles and job cuts
    Angus Liu writes an editorial warning that talks of a merger between AstraZeneca and Bristol Myers Squibb could create more problems than benefits. He notes that the two companies have only discuss…
    Fierce Biotech · 2d agoDealNegative↗ source
  • Analysts Question Potential AstraZeneca-Bristol Myers Megamerger
    Analysts are scrutinizing a recent report that suggests AstraZeneca could merge with Bristol Myers Squibb. The proposed megamerger has sparked a series of questions about strategic fit and executio…
    Endpoints · 1d agoDealNeutral↗ source
  • BioNTech appoints Sobi head Guido Oelkers as new CEO to steer oncology shift
    BioNTech announced that Guido Oelkers, who has led the rare‑disease focused Swedish company Sobi since 2017, will become its next chief executive officer. Oelkers is slated to take over the role b…
    BioPharma Dive · 1d agoNeutral↗ source
  • Supernus and Individor to merge, creating $2 billion brain-drug company
    Supernus and Individor announced a merger that will combine their portfolios of neurological medicines. The two firms together generated about $2 billion in revenue in 2025 from roughly a dozen CN…
    BioPharma Dive · 1d agoDealPositive↗ source